Tue, 22 October 2019
Biogen rises on news that it plans to file for FDA approval of its Alzheimers drug, Aducanumab. Under Armour gets a new CEO. And Hasbro tumbles on tariff trouble. Motley Fool analysts Andy Cross and Ron Gross tackle those stories and weigh in on the relative merits of Monopoly and Mr. Potato Head.
Thanks to Molekule for supporting our channel. Get 10% off your first air purifier at http://www.molekule.com with code fool10.